Patents by Inventor Kaiheng XIAO

Kaiheng XIAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10457747
    Abstract: Provided is a method for obtaining high-yield, stable expression cell clones from myeloma cell lines in a protein-free culture medium. The method is used for industrial production of a recombinant antibody, and includes three stage: (1) adapting to a protein-free culture medium, statically culturing cells at a low density, and gradually reducing a fat-rich supplement to a chemical culture medium; (2) adapting to a protein-free culture medium; culturing cells at a high density, and using a perfusion fermentation system in a laboratory scale; and (3) screening high-yield, stable expression cell clones from the cells after fermentation ends. The cell clone may be used to produce a humanized anti-NeuGcGM3 14F7 recombinant antibody.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: October 29, 2019
    Assignees: BIOTECH PHARMACEUTICAL CO. LTD., CENTRO DE INMUNOLOGIA MOLECULAR
    Inventors: MeyLen Chea, Julio Palacios, Miguel Arias, Loany Calvo, Tamara González, Rolando Pérez, Zhi Bai, Yuemao Liu, Kaiheng Xiao, Xiao Chen, Zhenhua He, Yangliu Cai, Zhenhua Yang, Xianhong Bai
  • Publication number: 20180016353
    Abstract: Provided is a method for obtaining high-yield, stable expression cell clones from myeloma cell lines in a protein-free culture medium. The method is used for industrial production of a recombinant antibody, and includes three stage: (1) adapting to a protein-free culture medium, statically culturing cells at a low density, and gradually reducing a fat-rich supplement to a chemical culture medium; (2) adapting to a protein-free culture medium; culturing cells at a high density, and using a perfusion fermentation system in a laboratory scale; and (3) screening high-yield, stable expression cell clones from the cells after fermentation ends. The cell clone may be used to produce a humanized anti-NeuGcGM3 14F7 recombinant antibody.
    Type: Application
    Filed: March 11, 2016
    Publication date: January 18, 2018
    Inventors: MeyLen CHEA, Julio PALACIOS, Miguel ARIAS, Loany CALVO, Tamara GONZÁLEZ, Rolando PÉREZ, Zhi BAI, Yuemao LIU, Kaiheng XIAO, Xiao CHEN, Zhenhua HE, Yangliu CAI, Zhenhua YANG, Xianhong BAI